EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Inclusion Criteria

• •1\. Patients with Epstein-Barr virus infections post allogeneic HSCT, primary immunodeficiencies or post solid organ transplant with:
• •Increasing or persistent quantitative EBV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and/or
• •progressive clinical symptoms attributable to EBV, including biopsy proven colitis, lymphadenopathy, hepatomegaly, splenomegaly AND/OR
• •Medical intolerance to anti-viral therapies including:
• •intolerance to rituximab Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.
• •Performance Status \> 30% (Lansky \< 16 yrs and Karnofsky \> 16 yrs) Age: 0.1 to 79.99 years Females of childbearing potential with a negative urine pregnancy test
• •2 Donor Eligibility 5.2.1 Related donor available with a T-cell response to the EBV MACS® GMP PepTivator antigen(s) causing the therapy-refractory EBV infection.
• •a. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party related allogeneic donor (family donor \> 1 HLA A, B, DR match to recipient) with IgG positive to EBV and/or a T-cell response at least to the viral MACS® GMP PepTivator EBV Select (containing among other antigens, NA-1, LMP2A and BZLF-1).
• •AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).
• •AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.